A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving
paren...
Age: 16 years - 66+
Gender: All
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving
paren...
Age: 16 years - 66+
Gender: All